Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Maternal Hyperoxygenation in CHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03944837
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : August 12, 2020
Sponsor:
Information provided by (Responsible Party):
Edgar Jaeggi, The Hospital for Sick Children

Brief Summary:
Congenital heart disease (CHD) is predominantly detected before birth. Using echocardiography and MRI, this study will determine whether acute exposure to maternal hyperoxygenation (MH) leads to measurable increases in fetal cerebral oxygenation from baseline in fetuses with CHD. The study aims to determine whether MH could be used as a chronic in-utero treatment strategy to promote brain growth/maturation to birth and to improve postnatal neurodevelopmental outcomes, and identify the types of CHD most likely to benefit from chronic MH.

Condition or disease Intervention/treatment Phase
Congenital Heart Disease Other: Oxygen gas Not Applicable

Detailed Description:

This study determines the impact of administering oxygen to mother during the later part of pregnancy on cerebral oxygen delivery in fetuses who were identified with severe forms of Congenital Heart disease (CHD) including the following groups:

  • Group 1: Single ventricular (SV) lesions, including hypoplastic left heart syndrome (HLHS); pulmonary atresia with intact ventricular septum (PA/IVS); tricuspid atresia (TA); unbalanced AV septal defect (AVSD); double inlet ventricle (DILV); and severe form of Ebstein's anomaly (EA with pulmonary atresia) of the tricuspid valve; and
  • Group 2: Tetralogy of Fallot (TOF),including TOF-like double outlet right ventricle (DORV), pulmonary atresia with ventricular septal defect (PA/VSD)
  • Group 3: Bi-ventricular lesions with transposition of the great arteries (TGA), including DORV with TGA

Children with severe CHD experience challenges in multiple developmental domains, impacting executive function, memory, language, and other aspects of cognitive and motor function. It is now well established that brain growth and development are adversely affected by CHD and it is increasingly clear that central nervous system changes that occur in the third trimester play a particularly important role in the pathogenesis of adverse neurodevelopmental outcomes.

Supplemental maternal oxygen will used in the last trimester for a short period of time (acute MH) in pregnant mothers carrying babies with CHD to briefly increase fetal oxygen levels to those reached in the newborn with spontaneous breathing. This study will examine whether and to what degree acute MH will improve the cerebrovascular oxygenation. The rate and duration of MH (10 to 15L/min by mask for up to 30-45 minutes/test) is considered to be safe to the mother and her fetus. Both fetal echocardiography and fetal MRI will be used to determine the effects of acute MH on the fetal-placental circulation and will determine in fetuses with CHD whether acute exposure to MH leads to measurable increases in fetal cerebral oxygenation from baseline. Thus it could potentially become useful as a chronic in-utero treatment strategy to promote brain growth/maturation to birth and to improve postnatal neurodevelopmental outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 170 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Congenital Heart Disease (CHD): Hemodynamic Effects of Acute Maternal Hyperoxygenation in the Fetus
Actual Study Start Date : April 26, 2019
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Severe fetal congenital heart disease (CHD)
Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
Other: Oxygen gas
Transient maternal oxygen administration during echocardiographic and MRI imaging




Primary Outcome Measures :
  1. Characterize the hemodynamic effects of acute MH on fetuses with a) SV lesions and biventricular anomalies b) with TOF and c) with TGA. [ Time Frame: Outcome measure obtained during hyperoxygenation while undergoing echocardiography and MRI ]
    The affect MH has on the cerebral oxygenation from baseline for each type of CHD will be characterized using the MRI variables of cerebral oxygen delivery (cDO2) and cerebral oxygen consumption(cVO2) , which are calculated using fluximetry measurements (ml/min/m2) and the oxymetry of the ascending aorta and the superior vena cava


Secondary Outcome Measures :
  1. Determine the pulmonary and placental vascular response to acute MH for each CHD [ Time Frame: Outcome measure obtained during hyperoxygenation while undergoing echocardiography and MRI ]
    The pulmonary and placental vascular response to acute MH for each CHD type will be measured using the placenta T2 star variable and the variables related to main pulmonary artery and branch pulmonary artery flow. Pulmonary vaso-reactivity to oxygen by echocardiography defined by a decrease the branch PA PI of ≥10%.


Other Outcome Measures:
  1. Assess the relationship between fetal brain volumes and cerebral oxygen delivery [ Time Frame: Outcome measure obtained during hyperoxygenation while undergoing echocardiography and MRI ]
    The fetal brain volumetry (mL) and rate of cerebral oxygen delivery (cDO2 ml/min/m2) at the time of the baseline fetal MRI will be compared

  2. To compare the prenatal measurement of placenta and the growth in body and brain size at birth. [ Time Frame: Date of echocardiography/MRI to the date of the infant's birth, when the birth weight, height and head circumference data become available. ]
    The placental measurement by MRI will be correlated with head circumference and body weight at birth.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pregnant mothers ≥18 years of age
  • Written maternal informed consent
  • Fetal diagnosis of one of the CHDs (1-3) as listed below and intention of active treatment after birth:

    1. Single ventricular (SV) lesions: hypoplastic left heart syndrome (HLHS); pulmonary atresia with intact ventricular septum (PA/IVS); tricuspid atresia (TA); unbalanced AV septal defect (AVSD); double inlet ventricle (DILV); and severe form of Ebstein's anomaly (EA) of the tricuspid valve associated with functional or anatomical right outflow obstruction. HLHS will include aortic stenosis with mitral stenosis, aortic atresia with mitral stenosis or mitral atresia. Pulmonary or aortic obstruction is defined as a condition with minimal or absent antegrade flow across the respective valve. Severe forms of EA is defined as lesion without anterograde pulmonary flow in the setting of severe tricuspid regurgitation.
    2. Bi-ventricular lesions with right ventricular outflow tract obstruction (BV/RVOTO); tetralogy of Fallot (TOF), TOF-like double outlet right ventricle (DORV), and pulmonary atresia with ventricular septal defect (PA/VSD).
    3. Bi-ventricular lesions with transposed great arteries (TGA w/ VSD; TGA w/o VSD; DORV with TGA)

Exclusion Criteria:

  • Termination of pregnancy
  • Unusual CHDs (e.g. EA with circular shunt, TOF with AVSD, and TOF with absent pulmonary valve syndrome, TGA associated with moderate- severe outflow tract obstruction
  • Complex cardiac condition (e.g poor fetal cardiac function and/or fetal hydrops, fetal arrhythmia such as frequent premature atrial beats, abnormal baseline heart rate (<110 bpm; > 160 bpm) in the third trimester)
  • Major non-cardiac lesions and major genetic abnormalities affecting brain size and development
  • Significant maternal co-morbidities that precludes a fetal MRI (e.g. significant obesity, claustrophobia)
  • Multiple pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03944837


Contacts
Layout table for location contacts
Contact: Edger Jaeggi, MD, FRCP(C) (416) 813-7466 edgar.jaeggi@sickkids.ca
Contact: Mika Saito, MD 46-813-7500 mika.saito@sickkids.ca

Locations
Layout table for location information
Canada, Ontario
The Hospital for Sick Children Recruiting
Toronto, Ontario, Canada, M5G1X8
Contact: Edgar Jaeggi, MD    4168137654    edgar.jaeggi@sickkids.ca   
Sponsors and Collaborators
The Hospital for Sick Children
Investigators
Layout table for investigator information
Principal Investigator: Edgar Jaeggi, MD, FRCP(C) The Hospital for Sick Children
Layout table for additonal information
Responsible Party: Edgar Jaeggi, Staff Cardiologist and Head of the Fetal Cardiac Program, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT03944837    
Other Study ID Numbers: 1000062939
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: August 12, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Edgar Jaeggi, The Hospital for Sick Children:
Acute maternal hyperoxygenation
Echocardiography
MRI
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Heart Defects, Congenital
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities